Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine.

Hensrud DD, Connolly HM, Grogan M, Miller FA, Bailey KR, Jensen MD.

Mayo Clin Proc. 1999 Dec;74(12):1191-7.

PMID:
10593346
2.

Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine.

Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL.

JAMA. 2000 Apr 5;283(13):1703-9.

PMID:
10755496
3.

Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine.

Gardin JM, Weissman NJ, Leung C, Panza JA, Fernicola D, Davis KD, Constantine GD, Reid CL.

JAMA. 2001 Oct 24-31;286(16):2011-4.

PMID:
11667938
4.

Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months.

Burger AJ, Sherman HB, Charlamb MJ, Kim J, Asinas LA, Flickner SR, Blackburn GL.

J Am Coll Cardiol. 1999 Oct;34(4):1153-8.

5.

Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine.

Ryan DH, Bray GA, Helmcke F, Sander G, Volaufova J, Greenway F, Subramaniam P, Glancy DL.

Obes Res. 1999 Jul;7(4):313-22.

6.

The longitudinal effects of fenfluramine-phentermine use.

Fleming RM, Boyd LB.

Angiology. 2007 Jun-Jul;58(3):353-9.

PMID:
17626991
7.

Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience.

Teramae CY, Connolly HM, Grogan M, Miller FA Jr.

Mayo Clin Proc. 2000 May;75(5):456-61.

PMID:
10807073
8.

The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs.

Khan MA, Herzog CA, St Peter JV, Hartley GG, Madlon-Kay R, Dick CD, Asinger RW, Vessey JT.

N Engl J Med. 1998 Sep 10;339(11):713-8.

9.

A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.

Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE.

N Engl J Med. 1998 Sep 10;339(11):719-24.

10.

Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs.

Burger AJ, Charlamb MJ, Singh S, Notarianni M, Blackburn GL, Sherman HB.

Int J Cardiol. 2001 Jul;79(2-3):159-65.

PMID:
11461737
11.

Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status.

Whigham LD, Dhurandhar NV, Rahko PS, Atkinson RL.

Int J Obes (Lond). 2007 May;31(5):850-7. Epub 2006 Dec 5.

PMID:
17146452
12.

Valvular heart disease associated with fenfluramine-phentermine.

Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV.

N Engl J Med. 1997 Aug 28;337(9):581-8. Erratum in: N Engl J Med 1997 Dec 11;337(24):1783.

13.

Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.

Wee CC, Phillips RS, Aurigemma G, Erban S, Kriegel G, Riley M, Douglas PS.

Ann Intern Med. 1998 Dec 1;129(11):870-4. Erratum in: Ann Intern Med 2000 Jan 18;132(2):167.

PMID:
9867728
14.

Valvular heart disease in fenfluramine- phentermine-treated patients: a comparison with control patients.

Wadden TA, Silvestry FE, Aber JL, Berkowitz RI, Foster GD, Sutton MG.

Obes Res. 1999 May;7(3):309-10. No abstract available.

15.

Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine.

Kancherla MK, Salti HI, Mulderink TA, Parker M, Bonow RO, Mehlman DJ.

Am J Cardiol. 1999 Dec 1;84(11):1335-8.

PMID:
10614800
17.

Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study.

Palmieri V, Arnett DK, Roman MJ, Liu JE, Bella JN, Oberman A, Kitzman DW, Hopkins PN, Morgan D, de Simone G, Devereux RB.

Am J Med. 2002 Jun 15;112(9):710-5.

PMID:
12079711
18.

Valvular heart disease with the use of fenfluramine-phentermine.

Surapaneni P, Vinales KL, Najib MQ, Chaliki HP.

Tex Heart Inst J. 2011;38(5):581-3.

19.

Dose effect of fenfluramine-phentermine in the production of valvular heart disease.

Tovar EA, Landa DW, Borsari BE.

Ann Thorac Surg. 1999 Apr;67(4):1213-4. No abstract available.

PMID:
10320298
20.

The fen-phen finale: a study of weight loss and valvular heart disease.

Wadden TA, Berkowitz RI, Silvestry F, Vogt RA, St John Sutton MG, Stunkard AJ, Foster GD, Aber JL.

Obes Res. 1998 Jul;6(4):278-84.

Supplemental Content

Support Center